Project Grant K23HL169934
Award Date
8/15/24
Completion Date
6/30/29
Dollars Obligated
$143K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $265,482 to the Regents of the University of Minnesota to conduct research on vibrotactile stimulation of the larynx as a treatment for refractory chronic cough. The project aims to refine the dosage parameters for this vibrotactile stimulation approach and then conduct a pilot randomized controlled trial to evaluate its effects on...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $364,318 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of North Carolina at Chapel Hill. The 5-year grant, awarded on September 1, 2024, will fund the adaptation and pilot testing of a family-centered intervention called SUCCEED-ICU, designed to improve long-term outcomes for survivors of acute respiratory failure. The project aims to: 1) Adapt the existing SUCCEED intervention...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $725,088 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Rush University Medical Center to conduct a hybrid type 1 effectiveness-implementation study on optimizing the effectiveness and implementation of COPD self-management treatment. The study aims to determine the optimal combination of self-management education, physical activity, and inhaler training components that produce the best outcomes on...
This $2,048,864 federal Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to characterize chronic rhinosinusitis (CRS) and olfactory dysfunction in young children with cystic fibrosis (YCWCF) and test whether highly effective cystic fibrosis transmembrane conductance regulator modulator therapy (HEMT) can improve these comorbidities. The research will leverage objective and subjective, non-invasive outcome measures to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $387,116 to the University of South Florida to research the sensory neuronal mechanisms underlying the development of house dust mite-induced airway hyperreactivity, a key characteristic of asthma. The 5-year award, effective May 1, 2025, aims to identify the specific nerve subtypes and signaling pathways activated by house dust mite...
This $116,625 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support a research study to characterize novel subtypes of abnormalities in airway and chest wall deformation in patients with Chronic Obstructive Pulmonary Disease (COPD). The study will leverage established datasets from nationwide longitudinal lung studies to investigate the associations between these airway and chest wall...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $1,372,795 in funding from January 2025 through December 2027 to the University of Washington. The primary objectives are to: 1) maintain the Cardiovascular Health Study (CHS) coordinating center and associated databases and activities, including 78 active ancillary studies; 2) assist investigators in developing new ancillary study...
This federal Project Grant award of $613,934 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research into the role of the aryl hydrocarbon receptor (AhR) signaling pathway in regulating airway smooth muscle responses during inflammation and asthma. The key objectives are to: 1) Determine the mechanisms of AhR expression and regulation in human airway smooth muscle under inflammatory conditions; 2) Investigate...
This federal Project Grant award, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), funds research to characterize alternative splicing related to chronic obstructive pulmonary disease (COPD) and cigarette smoke exposure in human airway epithelial cells. The $2,377,618 grant, awarded on August 1, 2024 with a completion date of May 31, 2028, will support the development of genome-wide splicing QTL (sQTL) maps in...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...